VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascul...(of words such as may could expect ...),Health

Date:6/11/2009

of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

    -- our ability to borrow additional amounts under the loan from Bay City
       Capital, which is subject to the discretion of Bay City Capital;
    -- our ability to obtain necessary financing in the near term, including
       amounts necessary to repay the loan from Bay City Capital by the
       September 14, 2009 maturity date (or earlier if certain repayment
       acceleration provisions are triggered);
    -- our ability to control our operating expenses;
    -- our ability to comply with covenants included in the loan from Bay
       City Capital;
    -- our ability to maintain the listing of our common stock on NASDAQ;
    -- our failure to timely recruit and enroll patients for the FDG-PET
       clinical trial, as well as any future clinical trial;
     -- our failure to obtain sufficient data from enrolled patients that can
       be used to evaluate VIA- 2291, thereby impairing the validity or
       statistical significance of our clinical trials;
    -- our ability to successfully complete our clinical trials of VIA-2291
       on expected timetables and the outcomes of such clinical trials;
    -- complexities in designing and implementing cardiovascular clinical
       trials using histological examinations, measurement of biomarkers,
       medical imaging and atherosclerotic plaque bioassays;

'/>"/>
SOURCE  VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 
Related medicine technology :

1. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
2. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
3. ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
4. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
5. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
6. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
7. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
8. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
9. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer